

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

An Unexpected Nucleophilic Displacement Involving 6-Bromo-4- chloro-5-cyanopyrrolo[2,3-d]pyrimidine with Methanolic Ammonia

Pranab K. Gupta^a; Sauro Vittori^a; Leroy B. Townsend^a

^a Department of Medicinal Chemistry, College of Pharmacy, and Department of Chemistry, University of Michigan, Ann Arbor, MI

To cite this Article Gupta, Pranab K. , Vittori, Sauro and Townsend, Leroy B.(1990) 'An Unexpected Nucleophilic Displacement Involving 6-Bromo-4- chloro-5-cyanopyrrolo[2,3-d]pyrimidine with Methanolic Ammonia', *Nucleosides, Nucleotides and Nucleic Acids*, 9: 1, 35 – 41

To link to this Article: DOI: 10.1080/07328319008045107

URL: <http://dx.doi.org/10.1080/07328319008045107>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

AN UNEXPECTED NUCLEOPHILIC DISPLACEMENT INVOLVING 6-BROMO-4-CHLORO-5-CYANOPYRROLO[2,3-d]PYRIMIDINE WITH METHANOLIC AMMONIA

Pranab K. Gupta, Sauro Vittori and Leroy B. Townsend*

Department of Medicinal Chemistry, College of Pharmacy, and Department of Chemistry, University of Michigan, Ann Arbor, MI 48109-1065

Abstract:

Treatment of 6-bromo-4-chloro-5-cyano-7-(2-deoxy-3,5-di-Q-p-toluoyl- β -D-erythro-pentofuranosyl)pyrrolo[2,3-d]pyrimidine (3) with methanolic ammonia afforded the unexpected 6-amino-4-chloro-5-cyano-7-(2-deoxy- β -D-erythro-pentofuranosyl)-pyrrolo[2,3-d]pyrimidine (4). Hydrogenation of 4 with palladium-charcoal afforded the dehalogenated product 5, an isomer of 2'-deoxytocyamycin.

Introduction:


During the past decade, a number of nucleosides possessing tricyclic aglycons have been isolated from naturally occurring sources and prepared by synthetic procedures. Several of these nucleosides have demonstrated the ability to function as biological probes, e.g. ϵ -adenosine¹, and as chemotherapeutic agents, e.g. 6-amino-4-methyl-8-(β -D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine² (TCN) and TCN 5'-phosphate (TCNP). The pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine nucleoside TCN has shown significant biological activity and the 5'-phosphate derivative (TCNP) is currently in clinical trials (phase-2). In view of the interesting metabolic disposition of TCN and TCNP, we initiated a study designed to synthesize 2'-deoxy TCN and related tricyclic nucleosides in order to study their chemotherapeutic activity and metabolic disposition.

For the synthesis of 2'-deoxy-TCN, we elected to start with the condensation of an appropriately substituted heterocycle, 6-bromo-4-chloro-5-cyanopyrrolo[2,3-d]pyrimidine (1), with the appropriate carbohydrate. This condensation furnished 6-bromo-4-chloro-5-cyano-7-(2-deoxy-3,5-di-Q-p-toluoyl- β -D-erythro-pentofuranosyl)pyrrolo[2,3-d]pyrimidine (3). Prior to ring annulation, we elected to remove the blocking groups in order

to provide a more facile isolation of the tricyclic product. Methanolic ammonia treatment of **3**, at room temperature, was used to remove the blocking groups from the carbohydrate moiety of **3**. However, instead of obtaining the expected 6-bromo-4-chloro-5-cyano-7-(2-deoxy- β -D-erythro-pentofuranosyl)pyrrolo[2,3-d]pyrimidine, we obtained an unexpected compound. It was subsequently determined that deprotection as well as a displacement of the 6-bromo group with ammonia had taken place. On the basis of spectral data and elemental analysis, the compound was assigned the structure 6-amino-4-chloro-5-cyano-7-(2-deoxy- β -D-erythro-pentofuranosyl)pyrrolo[2,3-d]pyrimidine (**4**). This site of nucleophilic displacement was very unexpected in view of a previous report³, in which the treatment of 6-bromo-4-chloro-5-cyano-7-(2,3,5-tri-O-acetyl- β -D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine³ with methanolic ammonia at 110°C in a sealed tube resulted in the removal of the protecting groups, and a displacement of the chloro group instead of the bromo group to give 4-amino-6-bromo-5-cyano-7-(β -D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine. However, our results were similar to a previous report⁴ where a different group was residing at N7 of this same heterocycle. Treatment of **3** with methanolic ammonia at 90°C in a sealed reaction vessel also gave only **4** as a major isolable product. A further increase in temperature resulted in major decomposition, including a cleavage of the glycosidic bond.

Molecular mechanics calculation⁵ of compound **3**, in comparison with the riboside counterpart, does not provide any definite clue to this surprising C6-bromo displacement over the C4-chloro group. However, it is of interest that in the minimum energy conformation of compound **3**, the carbon bearing the bromo group of the 2'-deoxyriboside compound is more accessible than the carbon bearing the bromo group of the corresponding riboside compound.

The structures of compound **3** and **4** were firmly established by IR, ¹H NMR^{6,10} and Mass spectroscopy. The ¹H NMR spectrum for compound **4**, shows a quartet at δ 6.68 (anomeric proton) with a peak width and shape which are supportive of the β -anomeric configuration¹⁰. The presence of a chloro group in compound **4** was established



by mass spectroscopy since the molecular ion (M^+) for **4** is at 309 and 311, due to the isotopic chlorine. This supports the nucleophilic displacement of a bromo group at C-6 vs chloro at C-4. Compound **4** was hydrogenated in the presence of Pd-charcoal, to obtain⁷ compound **5**. The UV spectral data for compound **5** is similar to that reported⁸ for the corresponding riboside analog of **5**. This provides very strong support for the glycosidic linkage assignment as N7. If the glycosidic linkage had been at N1 or N3, the

UV spectra would have been very different and also a nucleophilic displacement of the C-4 chloro would have been much more facile than that observed for the C-6 bromo group in compound 3.

Experimental:

General Procedures. Melting points were taken on a Thomas-Hoover Capillary melting point apparatus and are uncorrected. Nuclear magnetic resonance (^1H NMR) spectra were determined at 270 MHz with a IBM WP 270 SY spectrometer. The chemical shift values are expressed in δ values (parts per million) relative to the standard chemical shift of the solvent (DMSO- d_6). Ultraviolet spectra were recorded [λ_{max} nm ($\epsilon \times 10^{-3}$)] on a Hewlett-Packard 0450A spectrophotometer and the infrared spectra were measured on a Perkin Elmer 281 spectrophotometer. Elemental analysis were performed by M-H-W Laboratories, Phoenix, Arizona. Thin layer chromatography (TLC) was on Silica gel 60 F-254 plates (Analtech, Inc.). Mass spectral data were obtained on a Finnigan 4021 mass spectrometer. Detection of components on TLC was made by UV light (254 nm). Rotary evaporations were carried out under reduced pressure with the bath temperature below 35°C unless otherwise specified.

6-Bromo-4-chloro-5-cyano-7-(2-deoxy-3,5-di-O-p-toluoyl- β -D-erythro-pentofuranosyl)-pyrrolo[2,3-d]pyrimidine (3).

6-Bromo-4-chloro-5-cyanopyrrolo[2,3-d]pyrimidine³ (1, 1.1 g, 4.28 mmole) was dissolved in dry CH_3CN (100 mL). Sodium hydride (60% in oil, 0.19 g, 4.68 mmole) was added to this mixture which was then stirred for 30 minutes at room temperature under nitrogen. 1-Chloro-2-deoxy-3,5-di-O-p-toluoyl- α -D-erythro-pentofuranose⁹ (2, 1.72 g, 4.43 mmole) was added in one portion and the reaction mixture was stirred for an additional 2 hr. The reaction mixture was evaporated to dryness, the residue was suspended in hot ethyl acetate (200 mL) and the mixture was filtered to remove inorganic salts. The filtrate was evaporated, absorbed onto silica gel (10 g), and chromatographed on a column (4 x 30 cm) using silica gel (80 g, 60-200 mesh). Elution of the column with

toluene:ethyl acetate (98:2, v/v) gave the desired nucleoside 3, after evaporation of the solvent, as a foam (1.38 g, crude yield 53.0%); m.p. softens at 70° and melts at 110°C; UV: MeOH, 228 (18.60) 283 (4.53); pH 1, 235 (10.03); pH 11, 219 (27.70) 285 (5.50); ¹H NMR (DMSO-d₆): δ 8.58 (s, 1H, C₂-H), 7.8-7.98 (m, 4H, Ar-H), 7.18-7.32 (m, 4H, Ar-H), 6.62 (t, 1H, J = 7.5 Hz; peak width = 15 Hz, C_{1'}-H), 6.05 (m, 1H, C_{3'}-H) and other sugar protons; Mass: B + 1 (259); S + 1 (353).

6-Amino-4-chloro-5-cyano-7-(2-deoxy-β-D-erythro-pentofuranosyl)pyrrolo[2,3-d]-pyrimidine (4).

Compound 3 (2.0 g, 3.28 mmole) was combined with methanolic ammonia (80 mL, saturated at 0°C), and the mixture stirred at room temperature in a pressure bottle for 16 hr. The reaction mixture was evaporated to dryness, absorbed onto silica gel (12.0 g) and chromatographed on a column (2 x 60 cm) using silica gel (50 g; 60-200 mesh). Elution of the column with CHCl₃:CH₃OH (95:5) gave the desired compound 4. Evaporation of the solvent and crystallization of the residue from EtOH gave 4 (0.4 g, 38.5%); m.p. 212-213°C; UV: EtOH, 235 (17.50) 314 (9.23); pH 1, 234 (14.04) 312 (7.18); pH 11, 221 (28.40) 313 (11.73); Mass (M/e) 309; (B + 1) 194; (S + 1) 117; ¹H NMR (DMSO-d₆): δ 8.42 (s, 1H, C₂-H), 8.07 (brs, 2H, D₂O exchangeable, NH₂), 6.68 (q, 1H, J = 5.8, 9.4 Hz; peak width = 15.2 Hz, C_{1'}-H), 5.75 (brs, 1H, D₂O-exchangeable, OH), 5.38 (d, 1H, D₂O exchangeable, OH), 4.41 (m, 1H, C_{3'}-H), and other sugar protons.

Anal. Calcd. for C₁₂H₁₂ClN₅O₃•1/2 H₂O: C, 45.22; H, 4.10; N, 21.97; Cl, 11.12. Found: C, 45.27; H, 4.10; N, 22.12; Cl, 11.21.

6-Amino-5-cyano-7-(2-deoxy-β-D-erythro-pentofuranosyl)pyrrolo[2,3-d]pyrimidine (5).

MgO (0.05 g) and 5% Pd-charcoal (0.07 g) were added to compound 4 (0.05 g; 0.161 mmole) dissolved in EtOH (15 mL) and the mixture was hydrogenated on a Parr apparatus at 15 psi for 4 hr. The mixture was filtered through Celite, the filtrate concentrated in vacuo, and the residue crystallized from abs. EtOH-Et₂O to obtain a white

solid powder (5, 0.036 g, yield 82%); m.p. 192°C; UV: MeOH, 234 (11.53) 280 (4.080) 311 (4.24); pH 1, 239 (17.56) 302 (6.01); pH 11, 218 (28.30) 307 (4.83); ^1H NMR (DMSO- d_6): δ 8.58 (s, 1H, C₂-H); 8.52 (s, 1H, C₄-H), 7.91 (brs, 2H, D₂O-exchangeable, NH₂), 6.70 (q, 1H, J = 5.8, 9.4 Hz; peak width = 15.2 Hz, C₁'-H), 5.77 (t, 1H, D₂O exchangeable, OH), 5.41 (d, 1H, D₂O exchangeable, OH), 4.42 (m, 1H, C₃'-H) and other sugar protons. Mass (m/e): 275. Anal. Calcd. for C₁₂H₁₃N₅O₃: C, 52.36; H, 4.76; N, 25.44. Found: C, 52.18; H, 4.72; N, 25.44.

Acknowledgement: This research was aided in part by research grant #CH-299 from the American Cancer Society and in part with Federal Funds from the Department of Health and Human Services under research contract No. 1-A1-72641. The authors would also like to thank Ms. Rae Miller for assistance in the preparation of this manuscript and Mr. Jack Hinkley for large scale preparation of certain starting materials.

REFERENCES

1. N. K. Kochetkov, V. N. Shibaev and A. A. Kost, Tetrahedron Lett., 1993 (1970).
2. K. H. Schram and L. B. Townsend, Tetrahedron Lett., 4757 (1971).
3. R. L. Tolman, R. K. Robins and L. B. Townsend, J. Am. Chem. Soc., **91**, 2102 (1969).
4. M. Bobek, R.L. Whistler and A. Bloch, J. Med. Chem., **15**, 168, (1972). The treatment of 6-bromo-4-chloro-5-cyano-7-(2,3,5-tri-O-acetyl-4-thio- β -D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine with methanolic ammonia at 5°C afforded 6-amino-4-chloro-5-cyano-7-(4-thio- β -D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine and it was assumed that in this instance, a displacement of the 6-bromo group instead of the 4-chloro group was due to the influence of the unusual group at N-7.
5. O. Kennard and D. G. Watson in Molecular Data and Dimension, Crystallographic Data Center, Cambridge, England, Volume 1-13.

6. L.B. Townsend in Synthetic Procedures in Nucleic Acid Chemistry by Zorbach and Tipson, Volume 2, Chapter 7.
7. If a nucleophilic displacement of the 4-chloro group of 3 had occurred, this hydrogenation procedure would have provided 2'-deoxytoyocamycin [T. Maruyama, L. L. Wotring and L. B. Townsend, J. Med. Chem., 26, 25 (1983)] instead of the isomeric compound 5.
8. K. H. Schram and L. B. Townsend, J. Chem. Soc., Perkin Trans., 1, 1253 (1975).
9. C. C. Bhat in Synthetic Procedures in Nucleic Acid Chemistry by Zorbach and Tipson, Volume 1, p. 521.
10. R. A. Long, R. K. Robins and L. B. Townsend, J. Org. Chem., 32, 2751 (1967).

Received February 1, 1989.